Abstract
The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater. Patients were recruited from Jiangsu Province Hospital (Jiangsu Sheng, China). The R-GemOx regimen was administered intravenously: rituximab 375 mg/m2 on day 0; gemcitabine 1 g/m2 on day 1; and oxaliplatin 100 mg/m2 on day 1. The cycle was repeated every 14 days. Six cycles were planned if the patient achieved at least partial remission after the interim assessment. The primary endpoint was the proportion of patients who achieved an overall response at the end of treatment (defined as complete response plus partial response). Analyses were done by intention to trea...Continue Reading
Citations
Jun 30, 2019·Current Hematologic Malignancy Reports·Murali KesavanGraham P Collins
Nov 11, 2019·Annals of Hematology·Vanja ZeremskiEnrico Schalk
Apr 28, 2019·Investigational New Drugs·M Christina CoxGerardo Musuraca
Aug 23, 2020·Current Oncology Reports·Pamela Allen
Dec 5, 2020·Hematology·Nancy L Bartlett
Nov 25, 2020·The Oncologist·Mengyang DiAdam J Olszewski
Sep 26, 2020·Journal of Geriatric Oncology·Vicki A Morrison
Mar 7, 2021·Critical Reviews in Oncology/hematology·Alda Tavares, Ilídia Moreira
Mar 11, 2021·Therapeutics and Clinical Risk Management·Barbara Jezeršek NovakovićAleksander Novaković
Mar 26, 2021·Leukemia & Lymphoma·Clarisse CazellesCorinne Haioun
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashley E RoskoHeidi D Klepin
Jul 20, 2021·Archives of Biochemistry and Biophysics·Zeyuan WangQingjiang Chen
Mar 14, 2021·British Journal of Haematology·Raul CordobaToby A Eyre
Aug 21, 2021·Future Oncology·Saaya TsutsuéBruce Crawford
Sep 9, 2021·European Journal of Haematology·Marguerite BriandLaurent Balardy
Nov 2, 2021·Frontiers in Genetics·Chenxi XiangHui Liu